Please use this identifier to cite or link to this item: http://essuir.sumdu.edu.ua/handle/123456789/75186
Or use following links to share this resource in social networks: Recommend this item
Title Serous adenocarcinoma of fallopian tubes: histological and immunohistochemical aspects
Authors Hyriavenko, Nataliia Ivanivna  
Lyndin, Mykola Serhiiovych  
Sikora, Kateryna Oleksiivna  
Piddubnyi, Artem Mykhailovych  
Karpenko, Liudmyla Ivanivna  
Kravtsova, Olha Ivanivna
Hyriavenko, D.
Diachenko, O.
Sikora, Vladyslav Volodymyrovych  
Romaniuk, Anatolii Mykolaiovych  
ORCID http://orcid.org/0000-0002-9805-014X
http://orcid.org/0000-0003-4385-3903
http://orcid.org/0000-0002-9814-6512
http://orcid.org/0000-0002-6508-0131
http://orcid.org/0000-0002-5274-7021
http://orcid.org/0000-0002-4147-6879
http://orcid.org/0000-0003-2560-1382
Keywords carcinoma
serous
neoplasms
fallopian tubes
progesterone receptor
Ki-67
p53
Bcl-2
vascular endothelial growth factor
Type Article
Date of Issue 2019
URI http://essuir.sumdu.edu.ua/handle/123456789/75186
Publisher The Korean Society of Pathologists
License
Citation Serous adenocarcinoma of fallopian tubes: histological and immunohistochemical aspects / N. Hyriavenko, M. Lyndin, O. Diachenko et al. // Journal of pathology and translational medicine. – 2019. – №4. – С. 236. - https://doi.org/10.4132/jptm.2019.03.21
Abstract Primary cancer of the fallopian tubes (PCFT) has the lowest incidence of tumors of the female reproductive organs, but its mortality is quite high.1 It was first described in a small number of patients as sporadic observations. The cause, frequency, diagnosis, prevention, and treatment of PCFT are insufficiently illuminated in the modern medical literature. The incidence of malignant tumors of the fallopian tubes (FT) ranges from 0.14% to 1.8% among all malignant tumors of the female reproductive system.2-5 While it is difficult to identify the initial tumor process of tubo-ovarian tumors, FT malignant tumors are often regarded as a type of ovarian cancer. Consequently, these tumors are much more frequent in gynecologic practice.6,7 This causes significant discrepancies regarding reports of PCFT morbidity, which undoubtedly depends on the quality of morphologic diagnosis. Practically, FT carcinomas are found more frequently in oncogynecology. Moreover, they serve as the primary source for serous and mucinous tumors of the ovaries and peritoneum.8-11 Increased oncologic awareness and improved diagnostic methods have led to a relative increase in the PCFT detection rate in recent years.12 The main prognostically important criteria remain tumor clinical stage and their degree of malignancy.13,14 The rarity of PCFT has made it impossible to identify significant predictive factors thus far. Identification of tumor markers in PCFT tissue may provide important diagnostic and prognostic information about the biological properties of this neoplasm. Information about tumor hormonal status (estrogen receptor [ER] and progesterone receptor [PR]), proliferative potential (Ki-67), anti-apoptotic properties (p53 and Bcl-2), and ability to stimulate angiogenesis (vascular endothelial growth factor [VEGF]) will undoubtedly serve as the basis for a pathophysiologic understanding of the molecular properties of FT cancer. Further information may allow identification of new target therapeutic methods for PCFT. Investigation of these tumor parameters is the aim of this study.
Appears in Collections: Наукові видання (НН МІ)

Views

Australia Australia
1
Canada Canada
1
Germany Germany
1
Greece Greece
1
Ireland Ireland
9131845
Lithuania Lithuania
1
Netherlands Netherlands
8135
Singapore Singapore
1
Sweden Sweden
1
Ukraine Ukraine
72864351
United Kingdom United Kingdom
30288202
United States United States
522050851
Unknown Country Unknown Country
19
Vietnam Vietnam
4068

Downloads

China China
1
Germany Germany
634347479
Lithuania Lithuania
1
Ukraine Ukraine
185160974
United Kingdom United Kingdom
1
United States United States
409754224
Unknown Country Unknown Country
2
Vietnam Vietnam
9131847

Files

File Size Format Downloads
Hyriavenko_carcinoma.pdf 7,63 MB Adobe PDF 1238394529

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.